January Therapeutics, an emerging oncology research and development company, announces a panel of renown scientific advisors
January Therapeutics, Inc., was formed around a proprietary therapeutic platform dubbed the Chemistry-enabled Albumin Nanoparticle (CAN) Platform. The company recently named a number of experts to provide advice on the development of the various compounds in the January pipeline.
“We have assembled a distinctive group of respected leaders in the fields of cancer research and drug development,” said Sam Ellis, January’s CEO, “and we look forward to collaborating with them in the development of our promising pipeline of therapeutics.”
The scientific advisors include:
- Gary Schwartz, MD – Division Chief, Hematology/ Oncology and Deputy Director Columbia University Irving Cancer Center
- David Carbone, MD, PhD – Director, James Thoracic Center at Ohio State University
- John Nuss, PhD – Inventor of Cabozantinib, Cobimetinib, and Esazerenone. Previously UC Riverside, Chiron, Exelixis
- Bruce Roth, PhD – Inventor of Lipitor. Previously Parke-Davis, Warner-Lambert, Pfizer, Genentech